Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mittal, Naveen K
EMBARK, NCT04524390 / 2020-000974-22: Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai	Completed	2	75	Europe, US, RoW	Maralixibat, Formerly LUM001 and SHP625, Placebo	Mirum Pharmaceuticals, Inc.	Biliary Atresia	11/23	02/24
Guerra, Diana Anzueto
EMBARK, NCT04524390 / 2020-000974-22: Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai	Completed	2	75	Europe, US, RoW	Maralixibat, Formerly LUM001 and SHP625, Placebo	Mirum Pharmaceuticals, Inc.	Biliary Atresia	11/23	02/24
NCT05380401: Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants	Recruiting	N/A	328	US	Enfamil® DHA & ARA Supplement for Special Dietary Use, DHA/ARA Supplement	The University of Texas Health Science Center at San Antonio, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Premature	04/27	04/28
NCT04508348: Clinical Trial to Decrease Length of Stay in Infants With Neonatal Abstinence Syndrome With an Exclusive Human Milk Diet	Active, not recruiting	N/A	19	US	Human Milk, 100% Human Milk, Standard of Care, Mother's milk and/or formula	The University of Texas Health Science Center at San Antonio	Neonatal Abstinence Syndrome	03/25	03/25